The global insulin and diabetes pharmaceutical market is historically dominated by three major multinational corporations known as the "Big Three": Novo Nordisk, Eli Lilly and Company, and Sanofi. These pharmaceutical giants command the vast majority of worldwide insulin production, supplying traditional human insulins, modern rapid-acting analogs, long-acting basal formulations, and advanced automated delivery combination treatments to international healthcare systems.